BG105651A - Антагонист на витронектиновия рецептор - Google Patents

Антагонист на витронектиновия рецептор

Info

Publication number
BG105651A
BG105651A BG105651A BG10565101A BG105651A BG 105651 A BG105651 A BG 105651A BG 105651 A BG105651 A BG 105651A BG 10565101 A BG10565101 A BG 10565101A BG 105651 A BG105651 A BG 105651A
Authority
BG
Bulgaria
Prior art keywords
receptor antagonist
vitronectin receptor
vitronectin
osteoporosis
useful
Prior art date
Application number
BG105651A
Other languages
English (en)
Other versions
BG65118B1 (bg
Inventor
William Miller
Peter Manley
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of BG105651A publication Critical patent/BG105651A/bg
Publication of BG65118B1 publication Critical patent/BG65118B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Съединението има формула@@То е витронектинов рецепторен антагонист и е приложимо при лечението на остеопороза. Изобретението се отнася и до фармацевтично приемлива сол на посоченото съединение.
BG105651A 1998-12-04 2001-06-26 Антагонист на витронектиновия рецептор BG65118B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11090398P 1998-12-04 1998-12-04

Publications (2)

Publication Number Publication Date
BG105651A true BG105651A (bg) 2002-02-28
BG65118B1 BG65118B1 (bg) 2007-03-30

Family

ID=22335565

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105651A BG65118B1 (bg) 1998-12-04 2001-06-26 Антагонист на витронектиновия рецептор

Country Status (39)

Country Link
US (1) US6495560B1 (bg)
EP (1) EP1146874B1 (bg)
JP (1) JP4481504B2 (bg)
KR (1) KR100620485B1 (bg)
CN (1) CN1147300C (bg)
AP (1) AP1534A (bg)
AR (1) AR035006A1 (bg)
AT (1) ATE277043T1 (bg)
AU (1) AU754408B2 (bg)
BG (1) BG65118B1 (bg)
BR (1) BR9915879A (bg)
CA (1) CA2353415A1 (bg)
CO (1) CO5150166A1 (bg)
CZ (1) CZ20011963A3 (bg)
DE (1) DE69920518T2 (bg)
DK (1) DK1146874T3 (bg)
DZ (1) DZ2954A1 (bg)
EA (1) EA003254B1 (bg)
EG (1) EG24025A (bg)
ES (1) ES2229798T3 (bg)
HK (1) HK1042037B (bg)
HU (1) HUP0104804A3 (bg)
ID (1) ID28811A (bg)
IL (2) IL143390A0 (bg)
MA (1) MA25265A1 (bg)
NO (1) NO318895B1 (bg)
NZ (1) NZ511876A (bg)
OA (1) OA11724A (bg)
PE (1) PE20001563A1 (bg)
PL (1) PL195973B1 (bg)
PT (1) PT1146874E (bg)
SI (1) SI1146874T1 (bg)
SK (1) SK7452001A3 (bg)
TR (1) TR200101654T2 (bg)
TW (1) TW482673B (bg)
UA (1) UA71586C2 (bg)
UY (1) UY25824A1 (bg)
WO (1) WO2000033838A1 (bg)
ZA (1) ZA200104398B (bg)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020665A1 (es) * 2000-06-15 2002-08-14 Pharmacia Corp ACIDO CICLOALQUIL FENIL ALCANOICO COMO ANTAGONISTA DE INTEGRINAS OVß3
JP2004513953A (ja) * 2000-10-24 2004-05-13 メルク　エンド　カムパニー　インコーポレーテッド ジベンズオキサゼピンαＶインテグリン受容体アンタゴニスト
KR100854424B1 (ko) 2001-01-29 2008-08-27 3-디멘져널 파마슈티칼즈 인코오포레이티드 치환된 인돌 및 인테그린 길항제로서의 이들의 용도
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
EP1572690A1 (en) 2002-12-20 2005-09-14 Pharmacia Corporation Thiazole compounds as integrin receptor antagonists derivatives
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
TW200635902A (en) * 2004-12-21 2006-10-16 Smithkline Beecham Corp Methods and formulations
ES2622519T3 (es) 2010-07-14 2017-07-06 Novartis Ag Componentes heterocíclicos agonistas del receptor IP
ES2565826T3 (es) 2012-01-13 2016-04-07 Novartis Ag Pirroles fusionados como agonistas del receptor IP para el tratamiento de hipertensión arterial pulmonar (PAH) y trastornos relacionados
US9604981B2 (en) 2013-02-13 2017-03-28 Novartis Ag IP receptor agonist heterocyclic compounds
HUE063437T2 (hu) 2013-09-24 2024-01-28 Fujifilm Corp Nitrogént tartalmazó vegyületet vagy sóját vagy fémkomplexét tartalmazó gyógyászati készítmény

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687154B1 (fr) 1992-02-07 1995-05-12 Rhone Poulenc Rorer Sa Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
JP3960482B2 (ja) * 1995-06-29 2007-08-15 スミスクライン・ビーチャム・コーポレイション インテグリン受容体アンタゴニスト
AU4109297A (en) * 1996-09-27 1998-04-17 Merkler, H. Tank for liquids, particularly for chemically aggressive liquids
WO1998015278A1 (en) 1996-10-07 1998-04-16 Smithkline Beecham Corporation Method for stimulating bone formation
UY24949A1 (es) * 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos

Also Published As

Publication number Publication date
HUP0104804A3 (en) 2002-12-28
KR20010080669A (ko) 2001-08-22
PT1146874E (pt) 2005-02-28
DE69920518D1 (de) 2004-10-28
UA71586C2 (en) 2004-12-15
DE69920518T2 (de) 2005-09-22
EP1146874A4 (en) 2002-06-05
HUP0104804A2 (hu) 2002-05-29
BR9915879A (pt) 2002-02-13
SI1146874T1 (en) 2005-04-30
ID28811A (id) 2001-07-05
ZA200104398B (en) 2002-05-29
PE20001563A1 (es) 2001-02-09
HK1042037A1 (en) 2002-08-02
AU1750200A (en) 2000-06-26
EP1146874B1 (en) 2004-09-22
MA25265A1 (fr) 2001-10-01
EA200100618A1 (ru) 2001-12-24
DZ2954A1 (fr) 2004-06-20
CN1334730A (zh) 2002-02-06
EG24025A (en) 2008-03-26
CN1147300C (zh) 2004-04-28
EP1146874A1 (en) 2001-10-24
PL195973B1 (pl) 2007-11-30
EA003254B1 (ru) 2003-02-27
CZ20011963A3 (cs) 2001-11-14
NO318895B1 (no) 2005-05-18
ES2229798T3 (es) 2005-04-16
IL143390A (en) 2006-07-05
TW482673B (en) 2002-04-11
AU754408B2 (en) 2002-11-14
CA2353415A1 (en) 2000-06-15
AR035006A1 (es) 2004-04-14
OA11724A (en) 2005-01-26
NZ511876A (en) 2004-02-27
UY25824A1 (es) 2001-07-31
AP1534A (en) 2006-01-09
TR200101654T2 (tr) 2002-03-21
KR100620485B1 (ko) 2006-09-13
PL348702A1 (en) 2002-06-03
ATE277043T1 (de) 2004-10-15
CO5150166A1 (es) 2002-04-29
JP2003523931A (ja) 2003-08-12
NO20012732L (no) 2001-08-01
JP4481504B2 (ja) 2010-06-16
BG65118B1 (bg) 2007-03-30
US6495560B1 (en) 2002-12-17
NO20012732D0 (no) 2001-06-01
SK7452001A3 (en) 2001-12-03
DK1146874T3 (da) 2005-01-31
HK1042037B (zh) 2005-07-29
IL143390A0 (en) 2002-04-21
WO2000033838A1 (en) 2000-06-15

Similar Documents

Publication Publication Date Title
BG106586A (bg) Пиразолопиримидини като терапевтични средства
MX9805253A (es) Antagonistas del receptor de vitronectina.
AU6473601A (en) Gabapentin analogues for sleep disorders
AU4086101A (en) Sulphonamido-substituted bridged bicycloalkyl derivatives
IL149592A0 (en) Synthesis of 2'-deoxy-l-nucleosides
MX9700041A (es) Antagonistas de receptor de vitronectina.
GB0005251D0 (en) Therapeutic compounds
MX9605915A (es) Derivados de piperazina como antagonistas de 5ht1a.
TR200000786T2 (tr) Vitronektin reseptör antagonisti
BR9813208A (pt) Antagonista receptor de vitronectina
BG105651A (bg) Антагонист на витронектиновия рецептор
BG104740A (bg) Мета - азациклични аминобензоени киселини и технипроизводни, ефикасни като антагонисти на интегрина
BG104314A (bg) Антагонисти на витронектинов рецептор
AP2000001898A0 (en) Vitronectin receptor antagonists
HK1041199A1 (en) 2-Methyl-thieno-benzodiazepine formulation.
BG102589A (bg) 3-азетидинилалкилпиперидини или - пиролидини катотахикининови антагонисти
MX9800483A (es) Derivados de piperazina y su uso como antagonistas de 5-ht1a.
NZ515025A (en) Solvates of pymetrozine
BG104038A (bg) Използване на специфичен антагонист на рецептора 5нт2 за получаване на лекарствени средства за лечение на апнея по време на сън
HK1029937A1 (en) Use of phanquinone for the treatment of alzheimer s disease.
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
WO2001017959A3 (en) Vitronectin receptor antagonists
WO2000007544A3 (en) Vitronectin receptor antagonists
BG106151A (bg) Фармацевтичен комплекс
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу